favorable-risk rcc: frontline vegf tki/io combinations
Published 4 years ago • 82 plays • Length 5:15Download video MP4
Download video MP3
Similar videos
-
4:09
favorable-risk rcc: options for vegf tki monotherapy
-
3:15
a novel approach: tki/i-o combinations in rcc
-
9:05
mrcc: when is tki/i-o combination therapy appropriate?
-
4:27
vegf-tki therapy in first-line mrcc
-
5:04
favorable-risk rcc: factors in selecting therapy
-
9:57
how to select 1st line therapy for metastatic renal cell cancer?
-
23:20
intermediate-risk prostate cancer treatment - musc hollings
-
7:52
frontline treatment options for stage 4 rcc
-
8:07
vegf tki immunotherapy combinations for mrcc
-
9:16
frontline rcc treatment selection: io/io versus io/tki
-
0:59
dr. alva on tki monotherapy and combinations for rcc
-
7:18
vegf tki therapy in the adjuvant setting of rcc
-
1:34
fda approval of frontline nivolumab/ipilimumab combo in rcc
-
3:11
treatment options for intermediate/poor-risk rcc
-
1:08
che-kai tsao, md, considers the various i-o and tki combinations available for 1st line rcc
-
1:02
current status of vegf inhibitor/immunotherapy combinations in rcc
-
6:01
metastatic rcc: using frontline ipilimumab/nivolumab
-
5:01
vegf tki therapy after i/o in mrcc
-
2:07
dr. mcdermott on tki/immunotherapy combinations in rcc
-
6:45
the latest data on io/tki versus io/io in frontline rcc
-
2:16
dr. amin on toxicities with immunotherapy/tki combinations in rcc
-
1:35
dr. grigg on immunotherapy/tki combinations in rcc